Laboratorios Bagó has inaugurated a new Bioanalytical Center at its pharmaceutical plant in La Plata, approved by ANMAT and designed both for the development of new products and for conducting essential studies in the bioanalytical stage of the bioequivalence process. These trials are key to determining that a pharmaceutical product is bioequivalent to a reference product and thus ensure its efficacy, quality, and safety, allowing for accelerated processes, reduced times, and increased accuracy in the results.
This new center represents a further step in the company’s commitment to innovation and the incorporation of state-of-the-art technology to enhance the quality of its products and rigorous scientific development.
“Science and technology are advancing at an unprecedented rate, and as a company, we have a responsibility to accompany that evolution with concrete decisions,” said Edgardo Vázquez, General Manager of Laboratorios Bagó. He added: “This new step reflects our conviction that investing in innovation not only strengthens our processes but also allows us to improve access to safe, effective, and quality treatments, with a real impact on people’s quality of life.”
The Bioanalytical Center offers an optimized work environment, with more interconnected areas that promote collaboration between teams and streamline processes. Its inauguration is part of an innovation strategy that permeates all areas of the company.
This new space joins the select group of bioanalytical centers authorized by ANMAT, of which there are currently six in the country, positioning Bagó as a key player in strengthening local capabilities in clinical research and pharmaceutical development.
With a focus on accessibility, and on offering the highest quality and effectiveness to improve the health of the community, Laboratorios Bagó is currently working on more than 100 R&D projects with a high level of innovation and application of Artificial Intelligence. Among the technologies used, pharmacometric tools and in vitro and in silico methodologies stand out, which allow optimizing the development and control of products with high standards of quality, precision, and efficiency.
With more than 90 years of experience, the company has consolidated an innovation model that combines scientific excellence, technological development, and strategic alliances with scientific and academic organizations. As a result, it has obtained 148 patents, 56 of them for discoveries of original molecules, and 92 for manufacturing procedures.
